AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17509587 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E(2) therapy (100 microg/d)
Number of subjects: 137
Study 17509587 — intervention group
Group type: COMPARATOR
Intervention: Control group (regularly menstruating women)
Number of subjects: 137
Study 16865142 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% citric acid solution and photo‐activated disinfection
Number of subjects: 64
Study 16865142 — intervention group
Group type: COMPARATOR
Intervention: 20% citric acid and 2.25% sodium hypochlorite solutions
Number of subjects: 64
Study 12789897 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Treatment Program
Number of subjects: 0
Study 10828648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 50
Study 10828648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9348567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral UFT plus leucovorin
Number of subjects: 0
Study 9348567 — intervention group
Group type: COMPARATOR
Intervention: 5-FU plus leucovorin
Number of subjects: 0
Study 7934682 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 15 micrograms/kg and neostigmine 40 micrograms/kg
Number of subjects: 100
Study 7934682 — intervention group
Group type: COMPARATOR
Intervention: Atropine 8 micrograms/kg and edrophonium 0.75 mg/kg
Number of subjects: 100
Study 30667205 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exercise (endurance, resistance, and flexibility training for six months)
Number of subjects: 30
Study 30667205 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exercise
Number of subjects: 30
Study 29216361 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE2109 100 mg
Number of subjects: 76
Study 29216361 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE2109 200 mg
Number of subjects: 76
Study 29216361 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE2109 100 mg/1.0 mg/0.5 mg (add-back therapy)
Number of subjects: 76
Study 29216361 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE2109 200 mg (with E2/NETA)
Number of subjects: 76
Study 29216361 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE2109/E2/NETA (100/0.5/0.1 or 100/1.0/0.5)
Number of subjects: 76
Study 27344235 — intervention group
Group type: EXPERIMENTAL
Intervention: AL-Scan (Nidek CO, Aichi, Japan)
Number of subjects: 65
Study 27344235 — intervention group
Group type: COMPARATOR
Intervention: Lenstar LS 900 (Haag‐Streit AG, Köniz, Switzerland)
Number of subjects: 65
Study 27344235 — intervention group
Group type: COMPARATOR
Intervention: AL-Scan and Lenstar comparison
Number of subjects: 65
Study 27344235 — intervention group
Group type: EXPERIMENTAL
Intervention: AL measurements
Number of subjects: 65
Study 25102719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-free pumice
Number of subjects: 46
Study 25102719 — intervention group
Group type: COMPARATOR
Intervention: Oil-containing Prophy Paste
Number of subjects: 46
Study 23290909 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 97
Study 23290909 — intervention group
Group type: COMPARATOR
Intervention: PVC per-DDS TACE
Number of subjects: 97
Study 23290909 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC per-DDS
Number of subjects: 97
Study 20216564 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt-based drink with Bifidobacterium animalis ssp. lactis (B. lactis) BB-12
Number of subjects: 182
Study 20216564 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt-based drink without Bifidobacterium animalis ssp. lactis (B. lactis) BB-12
Number of subjects: 182
Study 18301060 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 1776
Study 18301060 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral suppression (by > 1.0 log10 copies/ml or to < 400 copies/ml)
Number of subjects: 1776
Study 18301060 — intervention group
Group type: COMPARATOR
Intervention: Higher CD4 cell counts
Number of subjects: 1776
Study 16463698 — intervention group
Group type: EXPERIMENTAL
Intervention: CHC patients
Number of subjects: 29
Study 16463698 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29
Study 12185552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 3 mg
Number of subjects: 12
Study 12185552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg
Number of subjects: 12
Study 12185552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10360912 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary LH monitoring timed IUI
Number of subjects: 141
Study 10360912 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG-timed IUI
Number of subjects: 141
Study 7815583 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak velocity flow measurement using color duplex Doppler ultrasound
Number of subjects: 27
Study 7815583 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal peak velocity flow
Number of subjects: 27
Study 2007318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous furosemide
Number of subjects: 12
Study 2007318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral furosemide
Number of subjects: 12
Study 7133973 — intervention group
Group type: EXPERIMENTAL
Intervention: pirprofen (600 mg/day)
Number of subjects: 137
Study 7133973 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin (75 mg/day)
Number of subjects: 137
Study 7133973 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 137
Study 31652261 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic pheromone + insecticide
Number of subjects: 1454
Study 31652261 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-impregnated collars
Number of subjects: 1454
Study 31652261 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 1454
Study 29017796 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen tripeptide (CTP) 3.9g daily for 12 weeks
Number of subjects: 17
Study 29017796 — intervention group
Group type: COMPARATOR
Intervention: Normal collagen peptides (CP)
Number of subjects: 17
Study 29017796 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen tripeptide (CTP)
Number of subjects: 17
Study 26434023 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanation of correct technique of foot placement in barefoot running and running in minimalistic shoes (groups 2 and 4)
Number of subjects: 39
Study 26434023 — intervention group
Group type: COMPARATOR
Intervention: No explanation of correct technique (groups 1 and 3)
Number of subjects: 39
Study 22782256 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement (SARC) iCem (Heraeus Kulzer)
Number of subjects: 88
Study 22782256 — intervention group
Group type: COMPARATOR
Intervention: Resin-modified glass ionomer cement (RMGIC) GC Fuji PLUS
Number of subjects: 88
Study 21844964 — intervention group
Group type: EXPERIMENTAL
Intervention: CQS-01 device
Number of subjects: 86
Study 21844964 — intervention group
Group type: COMPARATOR
Intervention: EMS-III device
Number of subjects: 86
Study 19531413 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap arthroplasty
Number of subjects: 16
Study 19531413 — intervention group
Group type: COMPARATOR
Intervention: Interpositional arthroplasty with temporalis myofacial flap
Number of subjects: 16
Study 17341247 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/d of micronized 17beta-estradiol (estrogen therapy, n=32)
Number of subjects: 57
Study 17341247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 57
Study 15226327 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin (DC)
Number of subjects: 319
Study 15226327 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (D)
Number of subjects: 319
Study 11153533 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg daily for 2 weeks)
Number of subjects: 8
Study 9556465 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive pressure support ventilation
Number of subjects: 50
Study 9556465 — intervention group
Group type: COMPARATOR
Intervention: Invasive pressure support ventilation
Number of subjects: 50
Study 7831450 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0
Study 7831450 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 7831450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3342289 — intervention group
Group type: EXPERIMENTAL
Intervention: New tablet formulation of carbocysteine
Number of subjects: 0
Study 3342289 — intervention group
Group type: COMPARATOR
Intervention: Syrup containing carbocysteine
Number of subjects: 0
Study 3342289 — intervention group
Group type: COMPARATOR
Intervention: Capsules containing carbocysteine
Number of subjects: 0
Study 30048223 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mL irrigation volume
Number of subjects: 30
Study 30048223 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mL irrigation volume
Number of subjects: 30
Study 30048223 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 50 mL and 200 mL irrigation volumes
Number of subjects: 30
Study 29956087 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF)
Number of subjects: 0
Study 29956087 — intervention group
Group type: COMPARATOR
Intervention: Abacavir, Dolutegravir, and Lamivudine (ABC/DTG/3TC)
Number of subjects: 0
Study 28114399 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Monochord
Number of subjects: 42
Study 28114399 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation music
Number of subjects: 42
Study 26673534 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D imaging in large training box
Number of subjects: 24
Study 26673534 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D imaging in small training box
Number of subjects: 24
Study 26673534 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D imaging in both boxes
Number of subjects: 24
Study 26673534 — intervention group
Group type: COMPARATOR
Intervention: 2D imaging in large training box
Number of subjects: 24
Study 26673534 — intervention group
Group type: COMPARATOR
Intervention: 2D imaging in small training box
Number of subjects: 24
Study 23371792 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminding during the presentation of later instances
Number of subjects: 0
Study 23371792 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no reminding)
Number of subjects: 0
Study 23371792 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminding
Number of subjects: 0
Study 21683750 — intervention group
Group type: EXPERIMENTAL
Intervention: EmulGold(®) (EG) at doses of 40 g
Number of subjects: 0
Study 21683750 — intervention group
Group type: EXPERIMENTAL
Intervention: PreVitae(®) (PV) at doses of 40 g
Number of subjects: 0
Study 21683750 — intervention group
Group type: EXPERIMENTAL
Intervention: EmulGold(®) (EG) at doses of 10 or 20 g
Number of subjects: 0
Study 21683750 — intervention group
Group type: EXPERIMENTAL
Intervention: EmulGold(®) (EG) at doses of 5 and 10 g
Number of subjects: 0
Study 21683750 — intervention group
Group type: COMPARATOR
Intervention: All doses of both gums compared to negative control
Number of subjects: 0
Study 21683750 — intervention group
Group type: COMPARATOR
Intervention: Negative control (250 ml of water)
Number of subjects: 0
Study 18459351 — intervention group
Group type: EXPERIMENTAL
Intervention: Oddball face (15% of trials)
Number of subjects: 0
Study 18459351 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel probe stimuli (15% of trials)
Number of subjects: 0
Study 18459351 — intervention group
Group type: COMPARATOR
Intervention: Frequent face (70% of trials)
Number of subjects: 0
Study 16550734 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 7 days
Number of subjects: 26
Study 16550734 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 7 days
Number of subjects: 26
Study 16550734 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily with clarithromycin 500 mg b.i.d. for 1 week
Number of subjects: 26
Study 16550734 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 26
Study 16550734 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg b.i.d.
Number of subjects: 26
Study 12910115 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy (before the 4th day of MV)
Number of subjects: 468
Study 12910115 — intervention group
Group type: COMPARATOR
Intervention: Translaryngeal intubation (control)
Number of subjects: 468
Study 12910115 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy
Number of subjects: 468
Study 11145281 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI treatment (30 mg lansoprazole/day for 8 weeks followed by 15 or 30 mg lansoprazole or 20 mg omeprazole/day for 12 months)
Number of subjects: 295
Study 11145281 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI treatment
Number of subjects: 295
Study 8794399 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education and management service
Number of subjects: 0
Study 8794399 — intervention group
Group type: COMPARATOR
Intervention: Baseline audit
Number of subjects: 0
Study 2000109 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant as prophylaxis (90 mg intratracheal dose at delivery)
Number of subjects: 479
Study 2000109 — intervention group
Group type: COMPARATOR
Intervention: Surfactant as rescue therapy (90 mg intratracheal dose several hours after delivery if criteria met)
Number of subjects: 479
Study 2000109 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant as prophylaxis (for infants ≤ 26 weeks' gestation)
Number of subjects: 479
Study 2000109 — intervention group
Group type: COMPARATOR
Intervention: Surfactant as rescue therapy (for infants ≤ 26 weeks' gestation)
Number of subjects: 479
Study 6519358 — intervention group
Group type: EXPERIMENTAL
Intervention: Propanolol
Number of subjects: 39
Study 6519358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 31663962 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 160
Study 31663962 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 160
Study 29728148 — intervention group
Group type: EXPERIMENTAL
Intervention: GTO group (Veterans with access to MISSION-Vet)
Number of subjects: 168
Study 29728148 — intervention group
Group type: COMPARATOR
Intervention: Non-GTO group (Veterans without access to MISSION-Vet)
Number of subjects: 168
Study 28031612 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelecture assignment (PLA) provided before the lecture
Number of subjects: 150
Study 28031612 — intervention group
Group type: COMPARATOR
Intervention: Direct lecture attendance without PLA
Number of subjects: 150
Study 24401940 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxalt (10‐mg rizatriptan)
Number of subjects: 66
Study 24401940 — intervention group
Group type: COMPARATOR
Intervention: Placebo labeled as placebo
Number of subjects: 66
Study 24401940 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo labeled as Maxalt or placebo
Number of subjects: 66
Study 24401940 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo labeled as Maxalt
Number of subjects: 66
Study 24401940 — intervention group
Group type: EXPERIMENTAL
Intervention: Open‐label placebo
Number of subjects: 66
Study 24401940 — intervention group
Group type: COMPARATOR
Intervention: Placebo under each information condition
Number of subjects: 66
Study 24401940 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxalt under each information condition
Number of subjects: 66
Study 23608089 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based voluntary HIV counselling and testing (HB-VCT) offered by local lay counsellors.
Number of subjects: 1694
Study 23608089 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based voluntary HIV counselling and testing (HB-VCT)
Number of subjects: 1694
Study 23608089 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV testing services (Control)
Number of subjects: 1694
Study 23608089 — intervention group
Group type: COMPARATOR
Intervention: Home-based voluntary HIV counselling and testing (HB-VCT) and Standard HIV testing services (Control)
Number of subjects: 1694
Study 20443650 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 5 mg
Number of subjects: 300
Study 20443650 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 2.5 mg
Number of subjects: 300
Study 20443650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 17588581 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of Candesartan (32 mg)
Number of subjects: 69
Study 17588581 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional doses of Candesartan (16 mg)
Number of subjects: 69
Study 17588581 — intervention group
Group type: COMPARATOR
Intervention: Control group (other antihypertensive treatment)
Number of subjects: 69
Study 16805936 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1 h‐1
Number of subjects: 24
Study 16805936 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine 0.2 microg kg‐1 h‐1
Number of subjects: 24
Study 16805936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 12499328 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol meal (23% of energy)
Number of subjects: 19
Study 12499328 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein meal (32% of energy)
Number of subjects: 19
Study 12499328 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (65% of energy)
Number of subjects: 19
Study 12499328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat meal (65% of energy)
Number of subjects: 19
Study 10690672 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg rectally 3 times during the first 24 hours postoperatively
Number of subjects: 50
Study 10690672 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 times during the first 24 hours postoperatively
Number of subjects: 50
Study 9374256 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated IOLs
Number of subjects: 19
Study 9374256 — intervention group
Group type: COMPARATOR
Intervention: Standard IOLs
Number of subjects: 19
Study 8263310 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine and d-amphetamine combination
Number of subjects: 12
Study 8263310 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 12
Study 8263310 — intervention group
Group type: EXPERIMENTAL
Intervention: l-fenfluramine
Number of subjects: 12
Study 8263310 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic fenfluramine
Number of subjects: 12
Study 3834831 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine hydrochloride (200 mg single dose)
Number of subjects: 12
Study 3834831 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (200 mg single dose)
Number of subjects: 12
Study 31884563 — intervention group
Group type: EXPERIMENTAL
Intervention: Local farmers surrounding Borena Saynit National Park
Number of subjects: 356
Study 31884563 — intervention group
Group type: COMPARATOR
Intervention: Local farmers from unprotected villages
Number of subjects: 356
Study 31884563 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sites (Park boundaries and unprotected site)
Number of subjects: 356
Study 31884563 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents from Park boundaries
Number of subjects: 356
Study 30419032 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual tomography method
Number of subjects: 393
Study 30419032 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance theory-based partitioning of the perceptual network
Number of subjects: 393
Study 26618395 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured insoles (worn for 5 weeks)
Number of subjects: 60
Study 26618395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no textured insoles)
Number of subjects: 60
Study 24774470 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailor‐made weight loss intervention and oral glucosamine sulfate
Number of subjects: 407
Study 23068560 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-hold after forced expiration
Number of subjects: 440
Study 23068560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breath-hold maneuver)
Number of subjects: 440
Study 19926502 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (25 mg daily for 15 days, then 12.5 mg daily for 15 days, then 6.25 mg daily for 15 days, then 6.25 mg on alternate days for 15 days)
Number of subjects: 60
Study 19926502 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg daily for the first month, then on alternate days for the second month)
Number of subjects: 60
Study 19926502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mg cellulose daily for the first month, then on alternate days for the second month)
Number of subjects: 60
Study 19061737 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electric muscle stimulation combined with conventional physical therapy (n=16; 78±8 y)
Number of subjects: 29
Study 19061737 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy alone (n=13; 76±10 y)
Number of subjects: 29
Study 16629642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2b (PEG‐IFN) + lamivudine
Number of subjects: 110
Study 16629642 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon alpha‐2b (PEG‐IFN)
Number of subjects: 110
Study 12969085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 217
Study 12969085 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 217
Study 12969085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 217
Study 11016132 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-phase social norm intervention
Number of subjects: 634
Study 11016132 — intervention group
Group type: COMPARATOR
Intervention: Standard campus psychoeducational prevention program (Control)
Number of subjects: 634
Study 8676836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (LBA) treatment
Number of subjects: 8